When a marketing authorisation (MA) is granted, it may feel like the finish line of a long regulatory journey. In reality, approval is only the beginning. For Marketing Authorisation Holders (MAHs), the post-approval phase introduces a broad and continuous set of responsibilities designed to ensure that authorised medicines remain safe, effective, compliant and continuously available throughout their lifecycle.
Regulatory requirements, technical standards and quality expectations evolve continuously. MAHs must therefore monitor legislative developments, assess their impact on authorised products and implement necessary updates without delay, while remaining inspection-ready.
This blog provides an overview of key post-approval responsibilities in the EU from a regulatory affairs and quality perspective, demonstrating that maintaining a marketing authorisation involves far more than handling occasional variations. Read also our other blog explaining the pharmacovigilance responsibilities.
What regulatory lifecycle activities must MAH manage after approval?
Variation management and lifecycle maintenance
Variation management forms the core of post-approval regulatory work. Once a product is authorised, the MAH must continuously maintain the marketing authorisation dossier so that it reflects the current scientific, manufacturing and safety status of the product.
Lifecycle activities typically include:
- launch-related notifications
- manufacturing site or process changes
- quality improvements and specification updates
- safety-driven updates such as Risk Management Plan (RMP), SmPC or labelling revisions
- administrative changes
- periodic submissions required under specific regulatory procedures
Management of post-authorisation commitments and regulatory compliance
MAs are often granted together with specific post-authorisation commitments or obligations defined during the assessment process. These may include post-authorisation studies, submission of confirmatory or missing data, stability updates or other follow-up measures related to product quality, safety or efficacy.The MAH is responsible for tracking these commitments, ensuring submissions are completed within agreed timelines and maintaining documented compliance with regulatory requirements. Failure to fulfil agreed obligations may impact the validity of the MA. If delays or challenges arise, the MAH must communicate proactively with competent authorities and agree on appropriate corrective actions or revised timelines.
Regulatory authority communication and MAH contact responsibilities
Clear and reliable communication with regulatory authorities is one of the most important responsibilities of a MAH. Authorities must always be able to reach the MAH quickly, especially when safety, quality, or supply issues arise. For this reason, every MAH must always have a dedicated contact person for the MA.
Beyond day‑to‑day communication, the MAH must keep authorities informed of any changes that may affect the product’s safety, efficacy, or quality. This includes updates to manufacturing processes, specifications, packaging, or any information that impacts the approved dossier. When new risks or critical findings emerge, the MAH is legally obliged to notify authorities without delay.
Pricing and reimbursement (P&R) activities
Regulatory responsibilities extend beyond approval into market access and commercialisation. Patient access depends on successful pricing and reimbursement (P&R) processes, where the MAH plays a central coordinating role.
Although MA procedures are harmonised at EU level, pricing and reimbursement decisions remain national. The MAH manages national submissions, ensures alignment between approved regulatory documentation and reimbursement requirements, and maintains accurate product information within national pricing and reimbursement systems.
Responsibilities continue after market entry through price notifications, updates and ongoing maintenance of regulatory product data across markets.
Maintenance of labelling, artwork and product information
Any updates to regulatory texts, including the Summary of Product Characteristics (SmPC), package leaflet (PIL) and labelling, must be accurately implemented across all markets and packaging components.
This includes managing multilingual artwork updates following approved variations and ensuring timely implementation in accordance with national requirements. Product information and artwork management represent some of the most visible and operationally demanding post-approval regulatory responsibilities.
Management of MA transfers, discontinuations and withdrawals
Even when a product approaches discontinuation, regulatory responsibilities continue. MAHs must notify authorities of MA transfers, withdrawals or discontinuations and carefully manage transition periods and remaining stock to ensure continuity of patient treatment.
What quality related activities must MAHs manage after approval?
In addition to regulatory maintenance activities, the MAH carries ongoing responsibility for product quality oversight and supply continuity throughout the lifecycle.
Supply chain oversight and product availability management
A key responsibility of the MAH is ensuring continuous and reliable product availability. This requires oversight of manufacturing performance and supply chain operations, as well as early identification of potential risks that could lead to shortages.
The MAH must ensure that appropriate technical and quality agreements are in place across the supply chain. When risks to availability emerge, the MAH coordinates investigations, collaborates with manufacturing and distribution partners and communicates proactively with authorities to support timely mitigation.
Even when manufacturing activities are outsourced, ultimate responsibility for product availability and compliance remains with the MAH.
Read also: How MAH can avoid medicinal product shortages
Ongoing product quality oversight and PQR management
The MAH is responsible for the review and evaluation of Product Quality Reviews (PQRs) for each authorised product. Where manufacturing is outsourced, technical agreements must clearly define responsibilities between the MAH and manufacturing sites.
PQR evaluations cover deviations, complaints, stability data and quality trends affecting product quality or supply continuity. Based on these assessments, the MAH determines whether regulatory actions, process improvements or corrective and preventive actions are required.
Through this oversight, the MAH links manufacturing performance, quality system outcomes and regulatory compliance throughout the product lifecycle.
Management of quality defects, complaints and product recalls
The MAH plays a central coordinating role in managing quality defects, complaints and product recalls. Responsibilities include maintaining clearly defined procedures, ensuring rapid communication with competent authorities and coordinating cooperation between manufacturers and third parties.
The MAH must maintain designated contact persons for defect and recall management and ensure product defect reporting is done without delay. Manufacturers must inform the MAH immediately when defects may lead to recalls or supply restrictions.
Recall procedures must remain robust and regularly tested, including mock recalls where appropriate, to ensure continuous readiness. The MAH must also be capable of receiving and managing alerts related to suspected falsified medicines or quality defects affecting authorised products.
Marketing authorisation approval is not the final step but the beginning of continuous lifecycle management. From regulatory compliance and quality oversight to product information maintenance and market access activities, MAHs play a critical role in ensuring that medicines remain safe, effective and accessible throughout their lifetime on the market.
Medfiles supports MAHs throughout the product lifecycle, from initial marketing authorisation applications to post-approval maintenance, regulatory compliance and quality oversight – acting as a reliable partner across all phases.
Author:
Elina Krannila, Senior Regulatory Affairs Expert
Elina is a pharmacist and has been working at Medfiles since 2011. She supports pharmaceutical companies throughout the entire product lifecycle, from new marketing authorisation applications to post-authorisation maintenance and regulatory compliance activities. Her daily work includes lifecycle management activities such as variations and notifications, as well as regulatory compliance tasks including medical, editorial and ethical review of marketing materials and quality tasks related to reporting of shortages and product defects.
